{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T06:35:17Z","timestamp":1778913317468,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.leukres.2025.107679","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T03:53:09Z","timestamp":1742183589000},"page":"107679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Comprehensive analysis of tyrosine kinase domain mutations and imatinib resistance in chronic myeloid leukemia patients"],"prefix":"10.1016","volume":"152","author":[{"given":"Somprakash","family":"Dhangar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandrakala","family":"Shanmukhaiah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0132-7211","authenticated-orcid":false,"given":"Jagdeeshwar","family":"Ghatanatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leena","family":"Sawant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nehakumari","family":"Maurya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babu Rao","family":"Vundinti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.leukres.2025.107679_bib1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/ajh.24275","article-title":"Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring","volume":"91","author":"Jabbour","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"5405","key":"10.1016\/j.leukres.2025.107679_bib2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.leukres.2025.107679_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229104","article-title":"Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells","volume":"15","author":"Baykal-K\u00f6se","year":"2020","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.leukres.2025.107679_bib4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1124\/pr.55.3.4","article-title":"Specific targeted therapy of chronic myelogenous leukemia with imatinib","volume":"55","author":"Deininger","year":"2003","journal-title":"Pharmacol. Rev."},{"issue":"4","key":"10.1016\/j.leukres.2025.107679_bib5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cancergen.2011.03.002","article-title":"Philadelphia Chromosome Symposium: commemoration of the 50th anniversary of the discovery of the Ph chromosome","volume":"204","author":"Chandra","year":"2011","journal-title":"Cancer Genet."},{"key":"10.1016\/j.leukres.2025.107679_bib6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-3-030-71913-5_10","article-title":"A review and an update of european leukemianet recommendations for the management of chronic myeloid leukemia","author":"Gugliotta","year":"2021","journal-title":"Chronic Myeloid Leuk."},{"issue":"19","key":"10.1016\/j.leukres.2025.107679_bib7","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.3390\/cancers13194820","article-title":"Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia\u2014from molecular mechanisms to clinical relevance","volume":"13","author":"Alves","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.leukres.2025.107679_bib8","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bcp.2010.04.003","article-title":"The bone marrow microenvironment as a sanctuary for minimal residual disease in CML","volume":"80","author":"Nair","year":"2010","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"10.1016\/j.leukres.2025.107679_bib9","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"issue":"sup1","key":"10.1016\/j.leukres.2025.107679_bib10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/10428194.2010.546920","article-title":"Mechanisms of resistance to BCR\u2013ABL kinase inhibitors","volume":"52","author":"Diamond","year":"2011","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.leukres.2025.107679_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13104-024-06772-1","article-title":"Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study","volume":"17","author":"Seman","year":"2024","journal-title":"BMC Res. Notes"},{"issue":"12","key":"10.1016\/j.leukres.2025.107679_bib12","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.3109\/10428190903332486","article-title":"Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions","volume":"50","author":"Markose","year":"2009","journal-title":"Leuk. Lymphoma"},{"issue":"11","key":"10.1016\/j.leukres.2025.107679_bib13","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.3109\/10428194.2016.1157868","article-title":"Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance","volume":"57","author":"Patkar","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2025.107679_bib14","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/BF02616092","article-title":"An improved technique of preparing bone-marrow specimens for cytogenetic analysis","volume":"14","author":"Shiloh","year":"1978","journal-title":"Vitro"},{"issue":"3","key":"10.1016\/j.leukres.2025.107679_bib15","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0014-4827(60)90138-5","article-title":"Chromosome preparations of leukocytes cultured from human peripheral blood","volume":"20","author":"Moorhead","year":"1960","journal-title":"Exp. Cell Res."},{"issue":"7731","key":"10.1016\/j.leukres.2025.107679_bib16","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(71)90287-X","article-title":"A rapid banding technique for human chromosomes","volume":"298","author":"Seabright","year":"1971","journal-title":"lancet"},{"issue":"5","key":"10.1016\/j.leukres.2025.107679_bib17","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1751-553X.2008.01100.x","article-title":"International Councilfor Standardization In Hematology. ICSH guidelines for the standardization of bone marrow specimens and reports","volume":"30","author":"Lee","year":"2008","journal-title":"Int. J. Lab. Hematol."},{"issue":"4","key":"10.1016\/j.leukres.2025.107679_bib18","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.4238\/vol7-4gmr485","article-title":"Analysis and comparison of clinicohematological parameters and molecular and cytogenetic response of two Bcr\/Abl fusion transcripts","volume":"7","author":"Polampalli","year":"2008","journal-title":"Genet Mol. Res"},{"key":"10.1016\/j.leukres.2025.107679_bib19","first-page":"93","article-title":"Detection of BCR-ABL mutations and resistance to imatinib mesylate","author":"Branford","year":"2006","journal-title":"Myeloid Leuk.: Methods Protoc."},{"issue":"4","key":"10.1016\/j.leukres.2025.107679_bib20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/hon.894","article-title":"Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent","volume":"27","author":"Kim","year":"2009","journal-title":"Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2025.107679_bib21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"issue":"D1","key":"10.1016\/j.leukres.2025.107679_bib22","doi-asserted-by":"crossref","first-page":"D754","DOI":"10.1093\/nar\/gkx1098","article-title":"Ensembl 2018","volume":"46","author":"Zerbino","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"10.1016\/j.leukres.2025.107679_bib23","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res."},{"key":"10.1016\/j.leukres.2025.107679_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13059-016-0974-4","article-title":"The ensembl variant effect predictor","volume":"17","author":"McLaren","year":"2016","journal-title":"Genome Biol."},{"issue":"22","key":"10.1016\/j.leukres.2025.107679_bib25","doi-asserted-by":"crossref","first-page":"11189","DOI":"10.1093\/nar\/gks918","article-title":"LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets","volume":"40","author":"Wilm","year":"2012","journal-title":"Nucleic Acids Res."},{"issue":"7571","key":"10.1016\/j.leukres.2025.107679_bib26","first-page":"68","article-title":"1000 Genomes Project Consortium. A global reference for human genetic variation","volume":"526","year":"2015","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.leukres.2025.107679_bib27","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1101\/gr.9.8.677","article-title":"dbSNP\u2014database for single nucleotide polymorphisms and other classes of minor genetic variation","volume":"9","author":"Sherry","year":"1999","journal-title":"Genome Res."},{"issue":"1","key":"10.1016\/j.leukres.2025.107679_bib28","doi-asserted-by":"crossref","first-page":"8018","DOI":"10.1038\/ncomms9018","article-title":"Rare variant discovery by deep whole-genome sequencing of 1,070 Japanese individuals","volume":"6","author":"Nagasaki","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.leukres.2025.107679_bib29","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1016\/j.csbj.2021.09.016","article-title":"Structure-guided machine learning prediction of drug resistance mutations in Abelson 1 kinase","volume":"19","author":"Zhou","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"4","key":"10.1016\/j.leukres.2025.107679_bib30","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nmeth0410-248","article-title":"A method and server for predicting damaging missense mutations","volume":"7","author":"Adzhubei","year":"2010","journal-title":"Nat. Methods"},{"issue":"W1","key":"10.1016\/j.leukres.2025.107679_bib31","doi-asserted-by":"crossref","first-page":"W452","DOI":"10.1093\/nar\/gks539","article-title":"SIFT web server: predicting effects of amino acid substitutions on proteins","volume":"40","author":"Sim","year":"2012","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"10.1016\/j.leukres.2025.107679_bib32","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ajh.26642","article-title":"Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2025.107679_bib33","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000331472","article-title":"Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients","volume":"127","author":"Meggyesi","year":"2011","journal-title":"Acta Haematol."},{"issue":"10","key":"10.1016\/j.leukres.2025.107679_bib34","first-page":"3530","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood, J. Am. Soc. Hematol."},{"issue":"12","key":"10.1016\/j.leukres.2025.107679_bib35","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.3324\/haematol.2009.010629","article-title":"High rates of durable response are achieved with imatinib after treatment with interferon \u03b1 plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial","volume":"94","author":"Guilhot","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2025.107679_bib36","first-page":"1","article-title":"A retrospective analysis of BCR-ABL-1 kinase domain mutations in frontline TKI resistant chronic myeloid leukemia patients: a single centre experience","author":"Datta","year":"2024","journal-title":"Indian J. Hematol. Blood Transfus."},{"issue":"10","key":"10.1016\/j.leukres.2025.107679_bib37","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1016\/j.clml.2018.06.031","article-title":"Comparison of frequency and sensitivity of BCR-ABL1 kinase domain mutations in Asian and white patients with imatinib-resistant chronic\u2013phase chronic myeloid leukemia","volume":"18","author":"Kim","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"25","key":"10.1016\/j.leukres.2025.107679_bib38","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"03","key":"10.1016\/j.leukres.2025.107679_bib39","doi-asserted-by":"crossref","first-page":"328","DOI":"10.4103\/ijmpo.ijmpo_115_17","article-title":"The role of mutation testing in patients with chronic myeloid leukemia in chronic phase after imatinib failure and their outcomes after treatment modification: single\u2011institutional experience over 13 years","volume":"38","author":"Chaitanya","year":"2017","journal-title":"Indian J. Med. Paediatr. Oncol."},{"issue":"19","key":"10.1016\/j.leukres.2025.107679_bib40","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.3390\/cancers13194820","article-title":"Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia\u2014from molecular mechanisms to clinical relevance","volume":"13","author":"Alves","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.leukres.2025.107679_bib41","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","article-title":"Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants","volume":"36","author":"Eide","year":"2019","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.leukres.2025.107679_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114828","article-title":"Evolution of BCR\/ABL gene mutation in CML is time dependent and dependent on the pressure exerted by tyrosine kinase inhibitor","volume":"10","author":"Vaidya","year":"2015","journal-title":"PloS One"},{"issue":"D1","key":"10.1016\/j.leukres.2025.107679_bib43","doi-asserted-by":"crossref","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","article-title":"COSMIC: somatic cancer genetics at high-resolution","volume":"45","author":"Forbes","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"10.1016\/j.leukres.2025.107679_bib44","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1073\/pnas.1321173111","article-title":"Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy","volume":"111","author":"Gibbons","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.leukres.2025.107679_bib45","first-page":"489","article-title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor\u2013resistant CML: frequency and clonal relationships","volume":"121","author":"Khorashad","year":"2013","journal-title":"Blood, J. Am. Soc. Hematol."},{"issue":"6","key":"10.1016\/j.leukres.2025.107679_bib46","doi-asserted-by":"crossref","first-page":"757","DOI":"10.6004\/jnccn.2005.0045","article-title":"Resistance to imatinib: mechanisms and management","volume":"3","author":"Deininger","year":"2005","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"7","key":"10.1016\/j.leukres.2025.107679_bib47","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1158\/1535-7163.MCT-10-0311","article-title":"Variant isoforms of BCR-ABL1 in chronic myelogenous leukemia reflect alternative splicing of ABL1 in normal tissue\u2013letter","volume":"9","author":"Khorashad","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"12","key":"10.1016\/j.leukres.2025.107679_bib48","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.3390\/ijms21124469","article-title":"Bcr-Abl tyrosine kinase inhibitors in the treatment of pediatric CML","volume":"21","author":"Carofiglio","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.leukres.2025.107679_bib49","first-page":"534","article-title":"Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study","volume":"135","author":"Soverini","year":"2020","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"10.1016\/j.leukres.2025.107679_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-016-2635-0","article-title":"In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants","volume":"16","author":"Soverini","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.leukres.2025.107679_bib51","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-019-0815-5","article-title":"Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper","volume":"12","author":"Soverini","year":"2019","journal-title":"J. Hematol. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T08:31:27Z","timestamp":1762245087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625000396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":51,"alternative-id":["S0145212625000396"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107679","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive analysis of tyrosine kinase domain mutations and imatinib resistance in chronic myeloid leukemia patients","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107679","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107679"}}